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Research on medullary thyroid carcinoma (MTC) over the last 55 years has led to a good understanding of the genetic defects and
altered molecular pathways associated with its development. Currently, with the use of genetic testing, patients at high risk for
MTC can be identiﬁed before the disease develops and oﬀered prophylactic treatment. In cases of localized neck disease, surgery
can be curative. However, once MTC has spread beyond the neck, systemic therapy may be necessary. Conventional chemotherapy
has been shown to be ineﬀective; however, multikinase inhibitors have shown promise in stabilizing disease, and this year will
probably see the approval of a drug (Vandetanib) for advanced unresectable or metastatic disease, which represents a new chapter
inthehistoryofMTC.Inthispaper,weexplorenewlyunderstoodmolecularpathwaysandthemostpromisingemergingtherapies
that may change the management of MTC.
1.Introduction
Medullary thyroid carcinoma (MTC) is a neuroendocrine
tumor derived from parafollicular cells of the thyroid gland
[1]. MTC represents less than 3% of thyroid carcinomas
in the United States [2]. The ﬁrst description of its major
histological features and characterization as a separate
entity was done in 1959 by Hazard et al. [3]. It was
then rapidly recognized that this carcinoma had distinctive
clinicalfeatures,inthatMTCwasfoundtobeassociatedwith
pheochromocytomas and other tumors, an association now
known as multiple endocrine neoplasia type 2 (MEN2) [4].
The identiﬁcation of familial cases led to the conclusion that
manyMTCswereprobablyhereditary[5].In1966,MTCwas
found to arise from the calcitonin-secreting parafollicular
cells [6]. Subsequently, calcitonin provocation tests with cal-
cium and/or pentagastrin were used to identify individuals
susceptible to familial MTC, and those individuals were
oﬀered prophylactic thyroidectomy [7].
Activating mutations of the Rearranged during Trans-
fection (RET) proto-oncogene were described for the ﬁrst
time in patients with familial forms of MTC in 1993 [8, 9].
Since then, several germline RET proto-oncogene mutations
have been found in almost 100% of hereditary MTCs.
Additionally, somatic RET proto-oncogene mutations have
been found in approximately 40% of patients with sporadic
MTC [10, 11]. These discoveries created new paradigms for
the management of MTC: (1) the identiﬁcation of germline
RET proto-oncogene mutation carriers would allow the
removal of the thyroid cells at risk for transformation early
in life (this paradigm is perhaps the most perfect example
of primary cancer prevention in humans to date), (2) the
identiﬁcation of several hidden familial medullary thyroid
cancers [12], and (3) the abnormally activated RET gene
might become a target to treat patients with advanced
sporadic and hereditary MTC. Our goal in this paper is
to describe the molecular pathways associated with MTC
tumorigenesis and emerging therapies against this disease
(Figure 1).
2. MTC and the RET Proto-Oncogene
Autonomous cell growth is the deﬁning feature of all
benign or malignant tumors. Malignant neoplasms have2 Journal of Thyroid Research
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Figure 1: From prevention of MTC to treatment of incurable disease. Ideal approach to familial forms of MTC (a) versus treatment options
in unresectable and/or extensive metastatic disease and/or progression. (b) ∗Every patient should be evaluated in an individual basis, and the
decision to treat as well as the indication is not always clear cut as one must take into consideration quality of life issues and adverse events
associated with treatment.
the capacity to invade the surrounding normal tissue and
metastasizetodistantsites.Moleculesthatareresponsiblefor
growth and other fundamental cell functions are frequently
mutated in cancers. An example of such molecules is the
tyrosine kinase (TK) receptors (Figure 2). TK receptors
are membrane-spanning proteins with large N-terminal
extracellular domains that act as ligand-binding sites and
intracellular domains that catalyze the transfer of the γ
phosphate of adenosine-5 -triphosphate (ATP) to hydroxyl
groups of tyrosines of target proteins. TKs control a wide
range of fundamental processes of cells such as the cell
cycle, proliferation, angiogenesis, diﬀerentiation, motility,
apoptosis, and survival.
The RET proto-oncogene is located in chromosome
10q11.2 [13] .T h eg e n eh a s2 1e x o n s[ 14]a n dc o d e sf o ra
receptor TK [15]. The RET receptor is a transmembrane
protein constituted by extracellular, transmembrane, and
cytoplasmatic domains. The extracellular domain has a
stretch of approximately 100 amino acids that are similar
to members of the cadherin family of Ca2+dependent cell
adhesion molecules [16]. The binding of calcium to this
cadherin-like domain is needed for conformational changes
necessary for the interaction with diﬀerent glial cell line-
d e r i v e dn e u r o t r o p h i cf a c t o rl i g a n df a m i l ym e m b e r s( G D N F ,
neurturin, artemin, and persephin) [17]. These ligands in
conjunction with a ligand-speciﬁc coreceptor (GFRα 1–4)
activate RET [18]. These ligands or coreceptors are not
always needed for RET activation [19]. Following RET
activation, speciﬁc tyrosine residues are phosphorylated.
Theseresiduesserveasdockingsitesforadaptorproteinsthat
link the receptor to the main signal transduction pathways.
Diﬀerent activated sites trigger the activation of diﬀerent
pathways. For instance, tyrosine 1015 is a binding site for
phospholipaseCthatactivatesproteinkinaseC(PKC).Other
examples are given by the phosphorylated γ tyrosine 981
whichisresponsibleforSrcactivationuponRETengagement
[20] and the phosphorylation of tyrosine 1062, several
a d a p t o ro re ﬀector proteins are recruited including Shc,
FRS2, Dok family proteins, insulin receptor substrate 2,
and Enigma [21]. Then, various pathways that regulate cell
survival, diﬀerentiation, proliferation, and chemotaxis [20]
are activated, including RAS-extracellular signal-regulated
kinase (ERK), phosphatidylinositol 3-kinase (PI3K)-Akt,
p58 mitogen-activated protein kinase (MAPK), and Jun N-
terminal kinase (JNK) [22]( Figure 3).
Mutated RET is expressed in derivatives of neural crest
cells, including hereditary and sporadic MTC and pheochro-
mocytoma [23]. These mutations are referred to as gain-of-
function, because they lead to either a constitutively active
TK or decreased speciﬁcity of the TK for its substrate [24].
3.RET Genotype-PhenotypeCorrelations
3.1. Sporadic MTC. Sporadic MTC constitutes 65% to 75%
of MTC cases [25]. The most frequent clinical presentation is
that of a thyroid nodule. Up to 75% of patients with palpable
MTC have nodal metastases in the central and ipsilateral
neckcompartments,and47%ofpatientswithpalpableMTC
have nodal metastases in the contralateral neck [26]. Distant
metastases frequently occur in the liver, lungs, and bones.Journal of Thyroid Research 3
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Figure 2: Simpliﬁed schematic representation of some of the TKs and pathways involved in MTC carcinogenesis as well normal physiology.
These TKs represent important targets of TKIs. Written in the gray box are the consequences of the activation of multiple pathways and not
of any one in particular.
Somatic mutations occur in 30% to 40% of cases
[10, 11]. Exon 16, codon 918 ATG → ACG mutation is the
most common somatic mutation in sporadic MTC [27].
This mutation is associated with larger tumors and a more
advanced disease stage at diagnosis [11].
3.2. Hereditary MTC. Hereditary MTC constitutes 25% to
35% of MTC cases [25]. Hereditary MTC is preceded by
C-cell hyperplasia and is usually bilateral and multicentric
[28]. Hereditary forms of MTC are caused by germline
RET proto-oncogene mutations and occurs as part of
the MEN2 syndromes. MEN2A is characterized by MTC
in almost 100% of gene carriers, pheochromocytomas,
and parathyroid tumors. The most common mutations in
MEN2A occur in one of six cysteine residues (codons 609,
611,618,620,630,and634)intheRETextracellulardomain.
The most frequently mutated residue found in patients
with MEN2A is cysteine 634, in which removal of one-
half of an intramolecular disulﬁde bond allows formation
of an intermolecular disulﬁde bond with a second mutant
molecule, thus leading to constitutive receptor dimerization
[29]. PI3K-Akt and MAPK pathways have been implicated in
MEN2A [30].
There are three variants of the syndrome: (1) MEN2A
with Hirschsprung disease, (2) MEN2A associated with
cutaneous lichen amyloidosis, and (3) familial MTC, in
which MTC is the only manifestation. Familial MTC RET-
mutation aﬀects the extracellular cysteine-rich region and
the TK domain. This variant tends to be the least aggressive
form of hereditary MTC.
MEN2B is the most distinctive and aggressive MEN2
syndrome. The most common mutations associated with
MEN2B are M918T and A883F. These mutations, unlike
MEN2A, are in the TK domain and lead to an activated
monomeric form, thus altering substrate speciﬁcity [29].
The PI3K/Akt cascade has been shown to be important in
the pathogenesis of MEN2B in cell lines [31].
4. TK ReceptorsOther Than RETInvolvedin
MTC Tumorigenesis
4.1. Epidermal Growth Factor Receptor. The epidermal
growth factor receptor (EGFR/HER-1/erbB1) is a TK recep-
tor. It is one of four homologous transmembrane receptors
(the others are HER-2/erbB-2, HER-3/erbB-3, and HER-
4/erbB-4) that mediate the actions of diﬀerent growth fac-
tors, such as epidermal growth factor, transforming growth
factor-α, and neuregulins [32]. The binding of ligands
to these receptors induces EGFR homo- and/heterodimer
formation, kinase domain activation, and phosphorylation
of speciﬁc tyrosine residue that serve as docking sites for
molecules that lead to the activation of several cascades,
including the MAPK and PI3K pathways [33].
EGFR oncogenic activation can occur due to several
mechanisms: excess ligand or receptor expression, activating
mutations, failure of inactivation, or transactivation through
receptor dimerization [34]. To date, two major types of
EGFR-targeting agents exists monoclonal antibodies and
small-molecule ATP-competitive TK inhibitors (TKIs) [35,
36]. PKI166, a potent EGFR kinase inhibitor, also decreases
RET autophosphorylation and signaling in cell extracts
despite lacking an eﬀect on RET kinase activity. PKI166
was tested in clinical trial in patients with MTC amongst
others. However, due to liver toxicities the development of
this drug was halted [37]. AEE788, another EGFR kinase
inhibitor, inhibits RET-induced growth at concentrations
below its half maximal inhibitory concentration (IC50) [38].
However, AEE788 does not have any active clinical trials4 Journal of Thyroid Research
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Figure 3: A summary of the signaling pathway mediated by RET.
in MTC patients. A study of 153 primary and metastatic
MTC samples revealed that although EGFR mutations were
rare, EGFR expression was higher in metastatic sites than
in primary tumor sites [39]. MTC samples associated with
RET 883and918mutationshadasigniﬁcantlylowernumber
of EGFR polysomes and a tendency toward less EGFR
immunopositivity compared with samples associated with
other RET mutations. Therefore, it is speculated that the
most aggressive RET mutations are less dependent on EGFR
activation, thereby explaining why EGFR inhibitors are less
eﬀective in codon 918-mutated cell lines than in codon 634-
mutated cell lines.
4.2. Vascular Endothelial Growth Factor. The vascular end-
othelial growth factor (VEGF) family of growth factors stim-
ulates angiogenesis, endothelial cell proliferation, migration,
survival, and vascular permeability by various TK receptors:
VEGFR-1, VEGFR-2, and VEGFR-3 [40]. There are several
ligandsforVEGFRs:VEGF-A(VEGF)bindstobothVEGFR-
1 and VEGFR-2; VEGF-B and placenta growth factor bind
to only VEGFR-1; and VEGF-C and VEGF-D are speciﬁc
ligands for VEGFR-3 [41].
Angiogenesis is one of the essential alterations in cell
physiology that predispose to malignancy in many tumors,
and it is fundamental in tumor growth and metastasis.
Many molecules have been implicated as positive regulators
of angiogenesis, including VEGF, hepatocyte growth factor,
interleukin-8, and platelet-derived growth factor (PDGF).
The major mediator of tumor angiogenesis is VEGF, which
signals mainly through VEGFR-2. Activation of this receptor
leads to a cascade of diﬀerent pathways, including PLC γ-
PKC-Raf-MEK-MAPK and PI3K-Akt [42]. Lymphangiogen-
esis is also involved in tumor biology, and since lymphatic
vessels arise from blood vessels, some of the angiogenic
mechanisms are also used in this process. VEGF-C and
VEGF-D stimulate both angiogenesis and lymphangiogen-
esis and link both processes [43]. VEGFR-3 is expressed
mainly in lymphatic endothelial cells and is thought to be
primarily involved in lymphangiogenesis.
MTC has at least twofold expression when compared
with normal thyroid tissue of VEGF and VEGF-R2 [44].
There is also an up to 20-fold increased expression of VEGF-
C and VEGF-R3 in metastatic MTC [45]. Overexpression
and activation of VEGFR-2 in MTC correlate with metastasis
[39].
4.3. c-MET. The c-met (MET) proto-oncogene codes for the
TK receptor of the hepatocyte growth factor [46]. MET is
animportantfactorintumorigenesis.Deregulatedactivation
of MET confers unrestricted proliferative, antiapoptotic, cell
motility/migration, invasive, metastatic, and angiogenenic
properties to cancer cells [47]. Silencing the endogenous
MET proto-oncogene, which is overexpressed in tumor cells,
has been proven to impair the invasive growth in vitro, to
decrease the generation of metastases in vivo, and to pro-
mote the regression of already established metastases [48].Journal of Thyroid Research 5
Table 1: Some of the TKIs currently used for the treatment of MTC in clinical trials and oﬀ-label.
Drug Oral daily dose Major targets
Vandetanib 100–300mg VEGFR-1, VEGFR-2, VEGFR-3, RET, EGFR
Sorafenib 400–800mg RET, VEGFR-2, VEGFR-3, Flt-3, PDGFRβ,K I T ,
RAF-1
Sunitinib
37.5mg every day
50mg daily 4 weeks on 2
weeks oﬀ
VEGFR-2, PDGFRβ,K I T ,R E T
Cabozantinib (XL184) 125–175mg/day MET, VEGFR-2, RET, KIT, Flt-3, Tie-2
E7080 24mg VEGFR-2, VEGFR-3, VEGFR-1, KIT, FGFR1,
PDGFR, EGFR
MET and hepatocyte growth factor coexpression has been
seen in a subset of MTC tumors and is associated with
multifocality in MTC [49].
5.TargetedTherapy
Diﬀerent TKs and pathways are abnormally activated in
MTC cells. Inhibiting only one receptor may induce other
TKs compensatory activation [50]. Therefore, simultaneous
inhibition of diﬀerent activated TKs may be the best way
to approach MTC (Table 1)[ 51]. To date, systemic targeted
therapy for MTC has been administered in the context
of clinical trials or has consisted of oﬀ-label use of drugs
approved for other solid tumors. In this section, we review
the most promising TK inhibitors against MTC.
5.1. Vandetanib. Vandetanib is a 4-anilinoquinazoline that is
available as an oral daily agent. It inhibits VEGFR-2, VEGFR-
3, RET, and to a lesser extent EGFR and VEGFR-1 [52].
The 4-anilinoquinazoline docks to the ATP binding pocket
of RET kinase, inhibiting it [53].
At pharmacologically relevant doses, vandetanib inhibits
tumor cell proliferation, survival, and angiogenesis without
leading to direct cytotoxic eﬀects on tumor or endothelial
cells [52]. In 2002, vandetanib was shown to inhibit the
kinase activity of NIH-RET/C634R (MEN2A) and NIH-
RET/M918T (MEN2B) oncoproteins in vitro and to inhibit
RET/MEN2B phosphorylation and RET/MEN2B-dependent
MAPK activation in vivo in NIH-RET/MEN2B [54]. Two
years later, a panel of point mutations targeting the RET
kinase domain in MEN2 and sporadic MTC was screened for
susceptibility to vandetanib. Most of the mutant oncopro-
teins(RET/E768D,RET/L790F,RET/Y791F,RET/S891A,and
RET/A883F) were sensitive to vandetanib, while mutations
substituting valine 804 either to leucine or to methionine
(as occur in some cases of MEN2A) rendered the RET
kinase signiﬁcantly resistant. This is probably due to steric
hindrance, because the Val804Gly mutation increased the
sensitivity of RET to vandetanib [55]. Mice carrying a RET
C634R mutation from a sporadic human MTC treated with
vandetanib had inhibition of tumor growth [56].
Inhibition of other kinases seems to be very important,
too. MTC metastases express more EGFR and VEGFR-2 than
primary tumor sites. Both EGFR and VEGFR-2 have been
shown to be phosphorylated in TT and MZ-CRC-1 cells
and inhibited by vandetanib. Yet, in the presence of active
RET, neither plays a prominent role in TT cell proliferation.
However, when RET activity is inhibited, overstimulation
of EGFR is able to partially replace RET through a partial
rescueoftheMAPKpathway.Insuchscenario,theinhibition
of EGFR by vandetanib was shown to prevent this rescue
of the MAPK pathway. These data support the idea that
dual inhibition of RET and EGFR is important, as it may
overcome the risk of MTC cells’ escaping from RET blockade
through compensatory overstimulation of EGFR [50].
In phase I clinical studies of patients with solid tumors
(not including MTC) [57], doses of vandetanib up to
300mg/day were well tolerated, and adverse eﬀects were
generally mild and controlled with either dose adjustments
or symptomatic therapy. The most common adverse events
were rash, diarrhea, fatigue, asymptomatic QTc prolonga-
tion, proteinuria, and hypertension. Since QT prolongation
was note as an adverse event, patients should have EKG and
electrolytes at baseline and at regular intervals during the
course of treatment.
In a phase II study, 30 adult patients with unresectable,
locally advanced, or metastatic hereditary MTC received
300mg/day of vandetanib [58]. The primary endpoint was
the objective response rate (ORR) according to the 2000
Response Evaluation Criteria in Solid Tumors (RECIST)
guidelines [59]. Objective partial responses (PRs) were
observed in 20% of patients, and the median duration of
PR was 10.2 months. Additionally, 53% of patients had
stable disease (SD) for a median of 24 weeks. In another
trial of vandetanib at 100mg/day (or up to 300mg/day in
cases with disease progression), patients with similar disease
characteristics achieved similar results (ORR 68%) [60].
Both trials showed a ≥50% reduction in calcitonin and
carcinoembryonic antigen levels from baseline. However,
the reduction in calcitonin levels did not correlate with the
degreeoftumorgrowthinhibition.ItseemsthatRETactivity
is required for ligand-induced calcitonin gene expression
[61]. In that sense, carcinoembryonic antigen levels may
be a better marker of tumor response to vandetanib. Of
interest, there was no apparent association between speciﬁc
RET germline mutations and response to treatment (no
patientswith804RET mutationwereincluded).Otherphase
I and II studies are ongoing to determine the eﬀectiveness of
vandetanib in sporadic MTC and its safety and eﬃcacy in
children and adolescents. (http://www.ClinicalTrials.gov/).6 Journal of Thyroid Research
Data on vandetanib have been presented to the United
States Food and Drug Administration (FDA), including
results from the largest randomized, double-blind, placebo-
controlled trial, which was conducted in 331 patients
with advanced unresectable or metastatic MTC, “Study
D4200C00058”. This trial showed that median progression-
free survival (PFS) was 11 months longer in the group
randomly assigned to vandetanib and 45% had an ORR. As
the drug seems to be eﬀective in stabilizing symptomatic
and/orprogressivedisease,itwilllikelybecometheﬁrstFDA-
approved drug for MTC.
Nuclear factor κB( N F - κB) activation can block cell-
death pathways and contribute to the oncogenic state by
drivingproliferation,enhancingcellsurvival,andpromoting
angiogenesisandmetastasis.NF-κBhasahighbaselineactiv-
ity in MTC cell lines through RET-induced phosphorylation,
ubiquitination, and proteosomal degradation of inhibitors
of NF-kB (IkB), which allows NF-κB to enter the nucleus
and bind to the DNA [62]. Bortezomib inhibits proteosome-
mediated IkB degradation in MTC cells, resulting in its accu-
mulation and thus preventing NF-κB translocation to the
nucleus [63], thereby leading to apoptosis. A phase I/II trial
of the combination of vandetanib plus bortezomib is cur-
rently recruiting patients (http://www.ClinicalTrials.gov/).
Patients with MTC will participate in the phase II study.
5.2. Sorafenib. Sorafenib is a small TKI that targets RET,
VEGFR-2, VEGFR-3, Flt3, PDGFR-β,K I T ,a n dt h eR A F
family serine/threonine kinases RAF-1 and BRAF. It inhibits
the growth of RET-driven tumors by a combination of
activities that target RET-dependent thyroid cancer cell
proliferation and VEGF-dependent tumor angiogenesis. In
vitro, sorafenib inhibits RET signaling and the growth of
RET-transfected ﬁbroblasts and human thyroid cancer cells
that harbor RET/PTC and RET/MEN2 oncogenes. Sorafenib
action is mainly cytostatic, but the drug also exerts a
proapoptotic eﬀect. Sorafenib has been shown to signiﬁ-
cantly reduce tumor growth in nude mice with xenograft
tumors derived from MTC cell lines [64]. Sorafenib has been
investigated in four phase I trials with diﬀerent doses and
administration schedules. A dose of 400mg orally twice daily
was found to be safe and generally well tolerated, and the
most frequently reported drug-related adverse events were
fatigue, anorexia, diarrhea, rash/desquamation, and hand-
foot syndrome. Hand-foot syndrome is characterized by
painful erythematous lesions that aﬀect the palmo-plantar
surface. It is the most common reported adverse eﬀect in
patients taking the multikinase inhibitors like sorafenib and
sunitinib. The lesions are pronounced on the pressure points
on the palms and the soles but can also aﬀect the margins
of the feet and skin between ﬁngers and toes. These lesions
are not life threatening but signiﬁcantly impair the quality
of life requiring dose reduction or even discontinuation of
the drug [65].Severe hematological, cardiovascular, hepatic,
and renal toxic eﬀects were not reported. Treatment-related
hypertension was reported in 5% to 11% of patients in
all four phase I trials. Sorafenib demonstrated evidence
of antitumor activity by inducing disease stabilization in
patients with refractory tumors, a ﬁnding that was consistent
with the results of preclinical studies [66]. No patients with
thyroid cancer were included in the phase I study. Because of
the role of RET signaling in MTC and the antitumor activity
exhibited by sorafenib in preclinical and in vitro studies,
MTC was recognized as a potential target for sorafenib.
In a small 2007 pilot study that included ﬁve patients
with metastatic MTC with excessive calcitonin secretion,
calcitonin secretion was decreased by >50% in all patients
after 3 months of treatment, and all patients were free of
calcitonin-related symptoms. After 6 months of therapy, one
patient had a complete response (CR), and patient had a
PR [67]. Sorafenib was administered orally at a dose of
400mg twice daily continuously in a larger, open-label phase
II study in patients with histologically conﬁrmed metastatic
or locally advanced MTC. Patients were monitored regularly
with physical examination and biochemical and radiologic
testing. In the event of any signiﬁcant drug-related adverse
event, the drug was withheld and restarted at a lower dose of
400 to 600mg/day with dose re-escalation as tolerated. The
median duration of therapy with sorafenib was 15 months.
ORR was assessed using RECIST version 1.0. Of the 15
evaluable patients in this study, all showed some degree of
tumor shrinkage. One patient achieved PR; 14 patients had
SD, eight of whom had SD ≥15 months; and one patient had
clinically progressive disease. Most patients had decreased
calcitonin levels 2 months after treatment initiation, but they
did not correlate with the degree or duration of response as
assessed using RECIST [68]. Sorafenib has been approved
by the FDA for treatment of renal cell and hepatocellular
carcinoma. Therefore, sorafenib is an option for patients
with advanced MTC who are not eligible for clinical trials
[69].
5.3. Tipifarnib. Tipifarnib inhibits farnesylation of RAS and
other proteins. Farnesylation is a type of lipid modiﬁcation
that is critical for the biological functionality including
several signal transduction proteins. Farnesyltransferase
inhibitors target multiple pathways, including the RAS path-
way,andareamongtheﬁrstsystematicallyinvestigateddrugs
in oncogene-targeted therapy.R A Sgenes encode proteins
involved in cell proliferation, diﬀerentiation, and adhesion
and apoptosis regulation. At least three associated genes (H-
RAS,K-RAS,andN-RAS)arepresentinmammaliancells.Of
all human tumors, 30% might have a mutated RAS isoform.
Thyroid cancer has mutations in all three RAS genes. In
in vitro studies, tipifarnib inhibited the growth of several
human tumor cell lines, and in in vivo studies, tipifarnib was
shown to inhibit colon and pancreatic cancer xenografts in a
dose-dependent manner. The antitumor eﬀects were mainly
due to decreased cell proliferation, antiangiogenesis, and
apoptosis. A phase I trial of tipifarnib in combination with
sorafenib in patients with advanced malignancies included
15 patients with thyroid cancer, eight of whom had MTC.
Three of the six patients who reached ﬁrst restaging had
PRs, whereas the others had some minor regressions and
hence SD lasting from 12 to 16 months. The most common
side eﬀects reported were rash, hyperglycemia, and diarrhea.
RET mutational analysis in these six patients revealed RET
mutations; thus, it is unclear whether the response toJournal of Thyroid Research 7
sorafenib and tipifarnib was entirely due to RET inhibition
by sorafenib [70]. In a previously reported case, the rate of
response rate to combination therapy was higher than that
reported for sorafenib alone. It should be noted that the RET
pathwayiscomplexandtheRETkinasecanactivateacascade
ofsignalingpathways.Tipifarnibcanalsoaﬀectvariousother
pathways, including Akt and MAP/ERK, and may have acted
synergisticallytoproducetheclinicalresponse[71].TheFDA
has not approved tipifarnib because of its inferior outcomes
in phase III trials in patients with other malignancies [72].
However, the data from trials of thyroid cancer so far
seemencouraging,andstudiescombiningvariousoncogene-
targeted therapies are needed.
Preclinical studies have shown that activating RET muta-
tions in V804 (V804L and V804M) causes resistance to
various structural classes, including vandetanib. Mutations
in V804 slightly aﬀect RET susceptibility to sorafenib, thus
indicating that a structurally diﬀerent inhibitor may be
used to overcome the mutational resistance to a particular
TKI [73]. This might be clinically signiﬁcant as a recent
study showed RET V804M (19.6%) is a prevalent cause of
hereditary MTC [74].
5.4. Sunitinib. Sunitinib is a derivative of indolinone and
inhibitstheactivityofmanyTKs,includingVEGFR,PDGFR,
KIT,andRET.Sunitinibexertsantitumoractivitybyaﬀecting
cell proliferation and survival in cancers in which these
receptors are involved [75]. Its inhibitory eﬀect on VEGF
and RET makes this drug a rational choice for treating MTC.
In a phase II study of sunitinib in patients with progressive
thyroid cancer that included six patients with MTC, disease
stabilization was seen in ﬁve of the six patients (83%)
[76]. Results from another phase II study that included
only patients with progressive MTC also showed responses.
Among the 23 patients evaluated, eight (35%) achieved PR,
with a median response duration of 37 weeks, and 13 (57%)
had SD, with a median response duration of 32 weeks [77].
A trial using a lower dose of 37.5mg/day in a continuous
manner included six patients with MTC. Three of the six
patients had an objective response [78]. The most common
drug-related adverse events were fatigue, diarrhea, palmar-
plantar erythrodysesthesia, neutropenia, and hypertension.
Sunitinib has been approved by the FDA as the treatment
of renal cell carcinoma and is therefore available for use in
selected patients with MTC not enrolled in a clinical trial
[69].
5.5. Cabozantinib (XL184). Cabozantinib (XL184) is a small
molecule that inhibits MET, VEGFR-2, RET, KIT, Flt-3, and
Tie-2 [79]. In the context of MTC, preclinical data have
demonstrated that XL184 can inhibit the proliferation of
cells harboring activated RET. In 2009, results of a phase
I trial that included 37 patients with MTC revealed that
44% of patients achieved at least 30% reduction in tumor
size, and 29% of patients conﬁrmed PR. There was no
correlation between RET mutation status (either germline
or somatic) and tumor response [80]. Side eﬀects included
fatigue, diarrhea, appetite loss, weight loss, hair hypopig-
mentation, and hypertension. Other eﬀects, such as elevated
aspartate aminotransferase, alanine aminotransferase, lipase
elevations, palmar/plantar erythema, and mucositis, were
dose dependent. Because of the noted antitumor eﬀects
of XL184, a phase III clinical trial called the “Eﬃcacy of
XL184 in Advanced Medullary Thyroid Cancer (EXAM)”
is recruiting patients (http://www.ClinicalTrials.gov/). The
purposeofthestudyistoevaluatePFSwithXL184compared
to PFS with placebo in subjects with unresectable, locally
a d v a n c e d ,o rm e t a s t a t i cM T C .
Recently, in addition to giving XL184 a generic drug
name, FDA had granted XL184 an orphan drug designation
for treatment of follicular, medullary, and anaplastic thyroid
carcinoma, and metastatic or locally advanced papillary
thyroid cancer.
5.6. E7080. E7080 inhibits VEGFR-1, VEGFR-2, VEGFR-3,
KIT, FGFR1, PDGFR, and to a lesser extent EGFR. This
drug has been shown to be a potent inhibitor of in vitro
angiogenesis in human small cell lung cancer via inhibition
of VEGF/VEGF-2 and the stem cell factor/KIT signaling
pathways. Via dual inhibition of VEGFR-2 and VEGFR-3,
E7080 has also been shown to decrease lymphatic vessel
density in the primary tumors of VEGFC-overexpressing
MDA-MB-231 mammary fat pad xenograft models as well
as within the metastatic nodules in the lymph nodes of nude
mice [81].
In phase I trials, E7080 caused hypertension and pro-
teinuria, which were the major dose-limiting toxic eﬀects
[82]. Other observed adverse events included thrombosis,
tachycardia, febrile neutropenia, and thrombocytopenia.
A phase II trial to evaluate the safety and eﬃcacy of
oral E7080 in medullary and iodine-131-refractory, unre-
sectable diﬀerentiated thyroid cancers is ongoing (http://
www.clinicaltrials.gov/). The primary purpose of the trial
is to determine the eﬀect of E7080 on the objective tumor
response rate according to RECIST.
5.7. Pazopanib. Pazopanib is an oral multikinase inhibitor.
In vitro studies have shown that it is a potent inhibitor of
VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α and −β,a n dK I T
[83]. The antineoplastic activity of pazopanib is primarily
due to its eﬀect on the angiogenic pathways. Phase II studies
of pazopanib for MTC are ongoing [84].
6. Conclusion
Research on MTC over the last 55 years has led to a good
understanding of the genetic defects and altered molecular
pathways associated with its development. Subsequently,
promising targeted therapies have been developed for pro-
gressive and advanced MTC. Multikinase inhibitors have
shown good results in terms of stabilizing disease, and this
year will probably see the approval of a drug for advanced
unresectable or metastatic MTC, which would represent a
new chapter in the history of this disease. The challenge
f o rt h ey e a r st oc o m ei st od i s c o v e rm o r ee ﬀective ways
to target multiple key pathological pathways as well as the
identiﬁcation of the individuals who will beneﬁt the most.8 Journal of Thyroid Research
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